Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial

Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial
ShareXFacebook

(MedPage Today) -- SAN DIEGO -- Half of heavily pretreated patients with platinum-refractory ovarian cancer (PROC) responded to an investigational antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6), a small study from China showed. Overall...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement